Revenue
2012
2013
2014
2015
2022
2023
2024
2025
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2011
2012
2013
2014
2015
2017
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $336,108 | $617,140 | $557,710 | $989,042 | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $0 | — | — | — | — | — | — | — | — |
| Research & development | $1.9M | $2.1M | $1.7M | $2.4M | $2.6M | $2.8M | $4.0M | $4.7M | $8.2M | $8.2M | $11.4M | $5.8M | $3.6M | $5.0M | $8.8M | $8.4M | $4.9M | — | — | — | — | — | — |
| Operating expenses | $5.6M | $5.1M | $3.5M | $4.4M | $4.7M | $5.0M | $6.3M | $8.1M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | −$5.3M | −$4.5M | −$2.9M | −$3.4M | −$4.7M | −$5.0M | −$6.3M | −$8.1M | −$13.3M | −$24.5M | −$24.7M | −$12.6M | −$13.0M | −$14.3M | −$21.4M | −$20.7M | −$12.3M | — | — | — | — | — | — |
| EBITDAderived | — | — | — | — | — | −$4.7M | −$5.6M | −$7.4M | −$12.6M | −$23.8M | −$24.0M | −$12.0M | −$12.4M | −$13.7M | −$20.8M | −$20.0M | — | — | — | — | — | — | — |
| Net income | −$5.4M | −$4.7M | −$3.1M | −$3.6M | −$5.5M | −$6.7M | −$6.9M | −$8.2M | −$13.5M | −$24.4M | −$24.5M | −$10.2M | −$27.7M | −$12.6M | −$19.4M | −$18.6M | −$12.3M | −$10.3M | −$10.0M | −$8.9M | −$11.8M | −$4.3M | −$3.2M |
| Basic EPSper diluted share | -$0.01 | -$0.01 | -$0.01 | -$0.01 | -$0.01 | -$0.02 | -$0.02 | -$0.02 | -$0.04 | -$0.12 | -$0.13 | -$0.06 | -$0.22 | -$0.11 | — | — | — | — | — | — | — | — | — |
| Diluted EPSper diluted share | -$0.01 | -$0.01 | -$0.01 | -$0.01 | -$0.01 | -$0.02 | -$0.02 | -$0.02 | -$0.04 | -$0.12 | -$0.13 | -$0.06 | -$0.22 | -$0.11 | — | — | — | — | — | — | — | — | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 9, 2026Form 4 | Pershing EdwardCEO | BuySeries D-1 Convertible Preferred Stock · derivative | 34.9K | $2.86 | $99.9K | 2.61M |
| Nov 22, 2024Form 4 | Pershing EdwardCEO | BuySeries D-1 Convertible Preferred Stock · derivative | 80.4K | $2.86 | $229.8K | 1.69M |